GLPG4876

GLPG4876 is an investigational **small-molecule** inhibitor of salt-inducible kinases, reported by Galapagos as a **SIK2/3 inhibitor** within its Toledo immunology program. It was described as a back-up compound to GLPG3970 and as belonging to a different chemical family, with intended use in **inflammatory and autoimmune diseases**. By inhibiting SIK signaling, GLPG4876 was designed to rebalance immune responses by modulating pro-inflammatory and anti-inflammatory cytokine production. Publicly available information indicates that it remained in **preclinical development**, with no marketed brand name or approved indication identified.